Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Nature Communications Année : 2018

Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy

Résumé

Triple-negative breast cancer (TNBC) lacks targeted therapies and has a worse prognosis than other breast cancer subtypes, underscoring an urgent need for new therapeutic targets and strategies. IRE1 is an endoplasmic reticulum (ER) stress sensor, whose activation is predominantly linked to the resolution of ER stress and, in the case of severe stress, to cell death. Here we demonstrate that constitutive IRE1 RNase activity contributes to basal production of pro-tumorigenic factors IL-6, IL-8, CXCL1, GM-CSF, and TGF beta 2 in TNBC cells. We further show that the chemotherapeutic drug, paclitaxel, enhances IRE1 RNase activity and this contributes to paclitaxel-mediated expansion of tumor-initiating cells. In a xenograft mouse model of TNBC, inhibition of IRE1 RNase activity increases paclitaxel-mediated tumor suppression and delays tumor relapse post therapy. We therefore conclude that inclusion of IRE1 RNase inhibition in therapeutic strategies can enhance the effectiveness of current chemotherapeutics.
Fichier principal
Vignette du fichier
s41467-018-05763-8.pdf (1.72 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

hal-01879955 , version 1 (16-07-2019)

Identifiants

Citer

Susan E. Logue, Eoghan P. Mcgrath, Patricia Cleary, Stephanie Greene, Katarzyna Mnich, et al.. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. Nature Communications, 2018, 9 (1), pp.3267. ⟨10.1038/s41467-018-05763-8⟩. ⟨hal-01879955⟩
155 Consultations
134 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More